LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Lista de Ações・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Fechado

1.16 -3.33

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.15

Máximo

1.21

Indicadores-chave
By Trading Economics
Rendimento	3.5M -20M
EPS	-0.32
Funcionários	49
EBITDA	6.8M -22M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+111.9% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	626K 75M
Abertura anterior	4.49
Fecho anterior	1.16

Pliant Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de jun. de 2026, 20:30 UTC

Ganhos

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 de jun. de 2026, 23:58 UTC

Conversa de Mercado

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 de jun. de 2026, 23:41 UTC

Conversa de Mercado

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 de jun. de 2026, 23:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 de jun. de 2026, 22:57 UTC

Conversa de Mercado

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 de jun. de 2026, 22:50 UTC

Conversa de Mercado

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 de jun. de 2026, 21:00 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

2 de jun. de 2026, 20:46 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:38 UTC

Ganhos

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 de jun. de 2026, 20:21 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:12 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Product Rev $594M

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Loss $177M >PANW

Comparação entre Pares

Variação de preço

Pliant Therapeutics Inc Previsão

Preço-alvo

By TipRanks

111.9% parte superior

Previsão para 12 meses

Média 2.67 USD 111.9%

Máximo 3 USD

Mínimo 2 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Pliant Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.